By Dr Michael Seiler

2019 got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession.

By Dr Mark Chao, et al.

New immunotherapies that integrate innate and adaptive immune responses may increase efficacy against many cancers, and have the potential to expan...

By Dr Menelas Pangalos & Steve Rees et al.

A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine.

By Helen Stewart-Miller and Dr Richard Massey

Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations.

By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen

The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture.

By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr

Large pharmaceutical companies have struggled to efficiently implement tools, technologies and platforms into their drug discovery and development ...

By Michelle Vierra

Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to t...

By Professor Zeynep Erden, et al.

Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a...